<?xml version="1.0" encoding="UTF-8"?>
<svg height="870.031005859375" width="672.0029907226562" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <path d=" M 0.05999799817800522 826.072021484375 L 22.619997024536133 826.072021484375 L 22.619997024536133 826.35546875 L 0.05999799817800522 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 837.4110107421875 L 33.959449768066406 837.4110107421875 L 33.959449768066406 860.031005859375 L 33.67599868774414 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 837.4110107421875 L 628.2703857421875 837.4110107421875 L 628.2703857421875 860.031005859375 L 627.9869995117188 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 826.072021484375 L 662.0029907226562 826.072021484375 L 662.0029907226562 826.35546875 L 639.3259887695312 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 33.731998443603516 L 662.0029907226562 33.731998443603516 L 662.0029907226562 34.015480041503906 L 639.3259887695312 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 0.0 L 628.2703857421875 0.0 L 628.2703857421875 22.677000045776367 L 627.9869995117188 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 0.0 L 33.959449768066406 0.0 L 33.959449768066406 22.677000045776367 L 33.67599868774414 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 0.05999799817800522 33.731998443603516 L 22.619997024536133 33.731998443603516 L 22.619997024536133 34.015480041503906 L 0.05999799817800522 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="72.057,74.463,78.587,82.711,85.117,88.44,93.805,97.929,102.054,104.427,109.792,117.263,119.28,121.717,126.23,129.495,132.76,135.208,141.433,144.31,146.327,148.701,154.066,158.19,162.315,164.744,167.621,173.845,175.862,178.293,181.558,183.964,186.343,190.079,192.096,194.113,196.547,200.672,203.548,207.673,211.409,215.533,219.658,222.534,224.94,226.958,230.22299999999998,232.658,235.534,237.552,241.288,245.412" y="37.76400000000001" svg_rhmargin="247.429" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[27] Koh YW, Lee HJ, Ahn JH, et al. Prognostic signi</text>
  <text x="247.464" y="37.76400000000001" svg_rhmargin="251.588" style="fill:#171615;font-family:MMHCMO+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="251.603,254.868,258.604,262.728,265.993,269.258,271.67,275.795,278.201,280.627,283.033,287.158,290.423,292.815,295.692,299.428,301.834,303.926,308.051,310.446,314.57" y="37.76400000000001" svg_rhmargin="316.976" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cance of the ratio of</text>
  <text x="88.442,92.178,96.302,99.179,103.303,105.32,109.445,111.851,115.116,116.843,120.967,124.232,128.357,130.763,133.639,137.764,141.888,146.094,148.111,150.128,151.82,154.226,158.351,160.096,162.114,165.849,171.991,176.116,180.24,184.365,187.63,191.366,193.772,197.03699999999998,198.814,202.079,206.204,210.328,214.453,216.859,219.73600000000002,221.433,223.839,227.963,230.84,232.601,236.725,239.602,242.867,246.603,249.48,251.886,253.633,256.898,260.634,264.758,268.023,271.288,274.165,275.911,280.036,283.772,286.178,288.195,291.46,295.585,297.99,300.867,302.612,308.365,310.382,312.788" y="46.721000000000004" svg_rhmargin="316.912" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">absolute neutrophil to lymphocyte counts for breast cancer patients with</text>
  <text x="88.442,92.955,98.319,100.337,104.461,109.826,112.232,116.356,120.481,123.357,125.375,127.781,129.798,133.534,135.663,138.069,141.80499999999998,144.166,147.902,152.027,156.152,158.565,164.789,169.302,174.667,178.791,181.197,185.322,188.587,192.323,196.059,198.465,200.482,204.218,206.235,208.641,212.37699999999998,214.856,216.874,220.999,223.36,227.484,230.749,234.874,238.61,242.734,244.752,248.876,252.612,256.348,260.547,262.95300000000003,265.31,268.186,271.451,273.857,276.263,278.281,282.405,286.228,288.245,290.593,295.494,299.618,305.76,309.885,314.009" y="55.678" svg_rhmargin="316.886" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour</text>
  <text x="88.442,92.955,94.973,99.099,101.116,103.636,107.761,111.887,116.012,120.137,122.155,126.28,130.406,132.424,136.549,140.674,144.799" y="64.63599999999997" svg_rhmargin="148.923" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Biol 2014;35:9823</text>
  <text x="148.933" y="64.63599999999997" svg_rhmargin="152.669" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="152.674,156.8,160.925" y="64.63599999999997" svg_rhmargin="162.942" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">30.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,92.565,96.69,99.566,103.302,106.567,108.973,110.946,115.07,117.08699999999999,119.053,123.566,126.831,130.955,133.361,135.379,139.504,141.502,146.867,148.884,150.913,158.384,162.12,165.385,169.51,171.527,174.792,176.81,179.687,181.694,184.571,188.695,190.712,192.692,195.957,198.363,200.345,204.081,206.099,208.11599999999999,210.096,212.502,216.626,219.032,221.909,225.645,229.769,233.894,237.159,240.035,243.771,246.177,248.195,251.931,255.196,257.203,261.328,264.204,267.469,269.448,273.573,275.979,278.009,282.133,285.398,287.804,291.929,294.805,298.93,300.947,304.683,307.948,309.924,314.049" y="73.59299999999996" svg_rhmargin="316.926" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[28] Forget P, Bentin C, Machiels JP, et al. Intraoperative use of ketorolac or</text>
  <text x="88.442,92.566,94.583,97.849,99.866,103.99,106.396,109.662,113.786,117.522,120.787,123.135,125.152,128.029,130.391,134.127,137.004,139.88,144.005,147.27,149.287,153.023,155.429,158.694,162.819,165.141,170.894,172.912,175.318,179.443,181.808,183.825,189.967,194.091,196.968,201.092,204.828,208.094,212.219,214.574,218.698,220.716,223.592,226.857,230.593,233.47,236.735,239.141,241.547,244.424,247.793,251.058,253.349,256.225,260.35,263.226,266.962,268.98,272.716,276.452,278.469,280.843,284.579,288.703,292.828,295.129,299.253,302.989,306.254,309.131,312.867,314.884" y="82.54999999999995" svg_rhmargin="316.901" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">diclofenac is associated with improved disease-free survival and overall</text>
  <text x="88.442,91.318,95.443,98.319,102.055,104.073,107.809,111.544,113.56099999999999,116.162,118.179,122.304,124.893,128.158,132.282,136.407,139.283,142.549,145.425,149.161,152.897,155.303,157.32,161.056,164.321,166.955,171.08,173.956,177.222,180.957,183.834,186.24,188.837,192.102,195.838,199.963,203.228,206.493,209.37,211.966,214.843,218.967,221.844,225.58,228.845,231.722,235.458,237.475,240.083,244.596,247.473,250.061,252.93800000000002,255.504,260.868,264.993,268.729,271.994,274.871,277.276,281.401,284.018,288.143,292.267,296.392,300.516,302.533,306.658,310.782,314.907" y="91.56399999999996" svg_rhmargin="316.924" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">survival in conservative breast cancer surgery. Br J Anaesth 2014;113:</text>
  <text x="88.442,90.46,94.585" y="100.52099999999996" svg_rhmargin="98.709" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">i82</text>
  <text x="98.703" y="100.52099999999996" svg_rhmargin="102.439" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="102.444,106.57" y="100.52099999999996" svg_rhmargin="108.587" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">7.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,92.954,97.078,100.343,104.468,108.592,111.469,113.875,118.713,124.855,126.872,131.696,137.061,140.797,143.674,147.41,150.675,154.411,159.247,165.471,167.488,172.342,176.855,180.121,182.997,187.122,191.901,197.265,199.28199999999998,204.145,207.411,209.817,214.633,218.369,220.386,222.403,227.218,231.343,234.219,237.485,241.609,243.626,246.892,249.298,251.315,255.439,259.175,264.066,266.472,270.597,273.86199999999997,278.692,281.569,285.693,287.711,290.976,295.812,299.937,302.343,307.151,309.557,313.681" y="109.47799999999995" svg_rhmargin="316.946" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[29] Bozkurt O, Karaca H, Berk V, et al. Predicting the role of the</text>
  <text x="88.442,92.566,95.443,98.708,101.114,103.99,107.256,110.991,113.397,119.539,122.804,126.929,129.335,132.998,137.123,140.388,144.512,146.918,149.795,153.919,158.044,162.168,164.185,166.202,169.845,172.251,176.376,179.937,181.954,185.69,191.832,195.956,200.081,204.205,207.544,211.279,213.685,216.95,220.526,223.402,227.138,229.544,231.562,235.687,239.29,241.307,245.432,249.04,251.446,255.571,258.836,262.419,265.296,269.421,272.297,276.033,278.05,281.786,285.522,287.539,291.161,295.285,297.69100000000003,301.308,304.573,308.309,311.186,313.203" y="118.43600000000004" svg_rhmargin="316.939" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">pretreatment neutrophil to lymphocyte ratio in the survival of early</text>
  <text x="88.442,90.848,93.724,95.742,99.866,101.883,105.149,107.554,111.679,114.944,118.68,122.416,124.822,126.839,130.575,133.83999999999997,136.399,140.524,143.4,146.666,150.402,153.278,155.684,158.225,161.49,165.226,169.35,172.615,175.88,178.757,181.297,185.421,189.157,191.563,193.58,196.846,200.97,203.376,206.253,208.26999999999998,210.774,213.651,216.16,220.673,226.038,232.18,238.322,240.877,245.001,249.126,253.25,257.375,259.392,263.516,267.641,269.658,273.783,277.907,282.031" y="127.39300000000003" svg_rhmargin="286.155" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">triple-negative breast cancer patients. J BUON 2015;20:1432</text>
  <text x="286.242" y="127.39300000000003" svg_rhmargin="289.978" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="289.984,294.108" y="127.39300000000003" svg_rhmargin="296.125" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">9.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,92.565,94.583,97.459,99.865,103.13,105.148,107.165,109.182,112.93,120.402,122.419,126.139,130.652,132.669,135.546,139.28199999999998,142.976,150.448,156.201,158.218,161.967,166.48,170.216,172.233,174.251,177.987,180.393,184.517,187.394,190.659,194.393,199.758,201.775,205.505,208.77,211.17600000000002,214.858,218.594,220.612,222.629,226.367,230.491,233.368,236.633,239.039,241.445,244.321,247.586,251.322,253.728,259.87,263.135,267.26,269.666,273.418,277.542,280.808,284.932,287.338,290.215,294.339,298.463,302.669,304.687,306.704,310.379,312.785" y="136.35000000000002" svg_rhmargin="316.909" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[30] Pistelli M, Lisa MD, Ballatore Z, et al. Pre-treatment neutrophil to</text>
  <text x="88.442,90.459,94.195,100.337,104.461,108.586,112.71,115.975,119.711,122.117,125.382,126.933,129.809,133.545,135.951,137.968,142.093,143.656,149.798,153.534,157.26999999999998,158.792,162.917,166.182,167.693,171.429,172.965,177.089,179.966,183.231,185.637,189.761,191.778,193.316,195.722,199.846,203.971,205.988,207.488,209.505,213.63,215.198,219.322,222.199,225.464,229.588,231.606,234.871,237.277,239.294,243.419,247.155,248.701,251.577,255.702,258.578,262.314,264.332,268.067,271.803,273.82,275.344,277.362,281.487,283.054,286.32,290.055,292.932,294.949,298.685,300.175,302.58,305.457,307.474,311.683,313.7" y="145.36400000000003" svg_rhmargin="316.965" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lymphocyte ratio may be a useful tool in predicting survival in early triple</text>
  <text x="88.442,92.566,95.831,99.567,103.303,105.709,107.726,111.462,114.727,117.239,121.364,124.241,127.506,131.242,134.118,136.524,139.065,142.33,146.066,150.19,153.455,156.72,159.597,162.137,166.261,169.997,172.403,174.42,177.686,181.81,184.216,187.093,189.10999999999999,191.614,196.127,203.599,208.964,211.513,216.877,220.613,224.738,228.003,231.268,234.145,236.682,240.807,244.931,249.055,253.18,255.197,259.322,263.446,265.464,269.588,273.712,277.837" y="154.32100000000003" svg_rhmargin="279.854" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">negative breast cancer patients. BMC Cancer 2015;15:195.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,94.194,96.212,99.088,101.106,104.371,108.107,112.232,116.445,121.81,123.827,128.01,133.375,137.499,140.764,144.96,149.085,152.35,155.615,159.351,163.476,166.741,170.866,175.062,179.575,184.088,186.105,190.311,195.676,197.694,201.429,204.695,208.431,211.696,213.713,217.918,221.654,223.672,227.797,231.977,237.342,239.359,243.542,246.807,249.213,253.463,257.199,259.216,261.233,265.425,271.178,275.303,279.484,281.889,286.014,289.279,293.486,297.611,300.876,303.753,305.77,309.506,312.771" y="163.27800000000002" svg_rhmargin="316.895" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[31] Dirican A, Kucukzeybek BB, Alacacioglu A, et al. Do the derived</text>
  <text x="88.442,92.566,95.831,99.956,102.362,105.238,109.363,113.487,117.612,119.629,121.646,124.211,126.617,130.74200000000002,133.282,135.3,139.035,145.177,149.302,153.426,157.551,160.816,164.552,166.958,170.22299999999998,172.794,175.67,179.406,181.812,183.83,187.955,190.538,194.274,198.398,202.523,205.05,207.456,211.581,214.84599999999998,217.352,221.476,224.741,228.866,231.272,234.148,238.273,242.397,246.603,248.621,250.638,253.179,255.585,259.71000000000004,262.25,264.267,268.003,274.145,278.269,282.394,286.518,289.783,293.519,295.925,299.19,301.761,304.638,308.374,310.78,312.797" y="172.236" svg_rhmargin="316.921" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio</text>
  <text x="88.442,92.566,95.443,98.708,102.832,104.85,108.115,110.521,113.044,117.168,120.045,124.17,127.905,132.03,136.154,139.031,141.048,143.925,146.433,148.451,152.576,155.107,159.232,162.108,165.374,169.109,171.986,174.392,176.932,180.198,183.933,188.058,191.323,194.588,197.465,200.73,203.236,205.642,209.766,212.172,214.687,217.56400000000002,220.073,225.438,227.455,229.473,233.598,236.117,242.258,246.383,249.648,253.772,255.789,258.338,262.463,266.587,270.712,274.836,276.853,280.978,285.102,287.12,291.244" y="181.19299999999998" svg_rhmargin="295.368" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">predict prognosis in breast cancer? Int J Clin Oncol 2015;20:70</text>
  <text x="295.426" y="181.19299999999998" svg_rhmargin="299.162" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="299.168,303.293,307.418" y="181.19299999999998" svg_rhmargin="309.435" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">81.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,92.177,96.301,100.426,104.55,108.286,112.411,115.538,120.904,122.92099999999999,126.083,130.597,132.614,135.879,137.897,139.914,143.179,145.585,150.95,154.686,158.906,160.923,163.8,165.817,169.082,172.228,177.593,179.60999999999999,182.772,188.526,192.262,195.138,199.263,202.528,205.731,213.203,217.716,219.733,222.851,226.116,228.52200000000002,231.695,235.431,237.448,239.465,242.636,248.777,252.043,256.167,258.573,261.45,265.574,269.698,273.823,275.84,277.858,279.875,281.892,285.628,291.77,295.895,300.019,304.255,307.52,311.256,313.662" y="190.14999999999998" svg_rhmargin="316.927" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[32] Suppan C, Bjelic-Radisic V, Garde ML, et al. Neutrophil/lymphocyte</text>
  <text x="88.442,91.318,95.054,97.46,99.477,103.602,107.036,111.16,114.896,117.773,121.265,125.39,129.515,132.944,137.07,139.946,143.211,147.401,149.418,152.683,155.089,157.107,160.843,164.10799999999998,167.582,171.707,174.584,178.014,182.138,185.015,189.139,192.875,197.061,201.185,204.062,206.468,208.485,211.75,215.201,218.937,222.673,224.691,228.815,232.07999999999998,235.553,237.571,241.696,245.191,249.316,252.193,255.458,259.194,262.071,264.47700000000003,267.924,271.189,274.925,279.049,282.315,285.58,288.457,291.96,296.084,299.82,302.226,304.244,307.509,311.633,314.039" y="199.10699999999997" svg_rhmargin="316.916" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ratio has no predictive or prognostic value in breast cancer patients</text>
  <text x="88.442,92.566,96.69,100.815,104.08,106.957,110.693,114.817,116.834,120.959,124.69500000000001,126.706,130.831,133.707,136.972,141.097,145.221,148.487,151.363,155.099,157.505,159.522,163.258,166.523,168.598,171.475,175.211,178.088,180.493,183.759,189.9,191.918,195.183,197.226,199.632,203.756,207.021,209.898,213.634,217.758,221.494,223.511,225.57,230.083,237.555,242.92000000000002,244.901,250.266,254.002,258.126,261.391,264.657,267.534,269.56,273.685,277.809,281.934,286.058,288.154,292.278,296.403,298.42,302.544,306.669,310.793,314.918" y="208.12099999999998" svg_rhmargin="316.935" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">undergoing preoperative systemic therapy. BMC Cancer 2015;15:1027.</text>
  <text x="72.057,74.463,78.588,82.712,85.11800000000001,88.441,94.665,98.789,102.914,106.65,109.926,112.803,114.82,118.147,125.618,129.354,133.479,136.741,142.106,144.123,147.456,152.822,156.946,160.211,164.336,167.638,173.392,175.409,178.693,181.958,184.364,187.65,191.386,193.403,195.42,198.761,203.274,205.292,208.557,212.293,216.029,218.434,221.7,225.825,229.146,233.271,236.147,239.412,243.537,247.661,250.926,253.803,257.539,259.945,261.962,265.698,268.96299999999997,272.343,276.467,279.732,283.857,286.263,289.139,293.264,297.388,301.513,303.53,305.547,307.953,310.359,314.484" y="217.07799999999997" svg_rhmargin="316.89" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[33] Hong J, Mao Y, Chen X, et al. Elevated preoperative neutrophil-to-</text>
  <text x="88.442,90.459,94.195,100.337,104.461,108.586,112.71,115.975,119.711,122.117,125.382,127.896,130.773,134.509,136.915,138.932,143.057,145.584,149.708,152.585,155.85,159.974,161.992,165.257,167.663,170.54000000000002,173.021,177.145,181.27,185.394,188.27100000000002,190.764,194.889,196.906,199.783,203.048,206.784,209.66,212.926,215.332,217.737,220.614,223.983,227.248,229.709,232.585,236.71,239.586,243.322,245.34,249.076,252.812,254.829,257.316,259.334,263.459,265.934,271.298,275.423,277.44,281.636,284.901,287.778,291.043,293.484,299.238,303.362,309.504,312.769" y="226.03599999999994" svg_rhmargin="316.893" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lymphocyte ratio predicts poor disease-free survival in Chinese women</text>
  <text x="88.442,94.195,96.212,98.618,102.743,105.222,109.346,112.223,115.488,119.224,122.172,124.578,127.047,130.312,134.048,138.172,141.438,144.703,147.579,149.596,152.16,157.061,161.186,167.327,171.452,175.576,178.453,180.957,185.47,187.488,191.612,193.629,196.15,200.274,204.399,208.523,212.648,214.665,218.789,222.914,225.004,229.129,233.253,237.378" y="234.99300000000005" svg_rhmargin="241.502" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">with breast cancer. Tumour Biol 2015;37:4135</text>
  <text x="241.512" y="234.99300000000005" svg_rhmargin="245.248" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="245.254,249.379,253.504" y="234.99300000000005" svg_rhmargin="255.521" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">42.</text>
  <text x="72.058,74.464,78.589,82.713,85.119,88.442,93.806,97.931,102.056,104.032,109.396,114.761,116.77799999999999,118.77,122.895,126.631,129.507,133.632,135.607,141.831,147.196,149.213,151.197,155.71,158.975,162.23999999999998,164.179,169.544,175.768,177.785,179.768,183.033,185.439,187.421,191.157,193.175,195.192,197.172,201.296,204.173,208.298,212.033,216.219,220.344,223.221,225.627,227.644,230.909,234.645,236.663,238.68,242.416,244.394,248.518,250.536,253.412,255.818,257.836,261.96,265.225,267.631,269.648,273.384,276.649,278.69,281.567,285.691,289.816,293.551,296.428,300.553,304.677,308.802,310.775,312.793" y="243.95000000000005" svg_rhmargin="316.917" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[34] Yun YK, Park HK, Lee KH, et al. Prognostically distinctive subgroup in</text>
  <text x="88.442,92.567,96.303,98.709,102.833,106.958,108.975,113.099,116.835,118.853,122.118,124.666,130.808,134.933,137.422,141.546,144.423,147.688,151.424,154.3,156.70600000000002,159.247,162.512,166.248,170.372,173.637,176.903,179.779,181.796,184.303,187.18,189.688,194.202,197.079,200.344,204.08,206.956,209.362,211.911,217.276,221.012,225.136,228.401,231.666,234.543,237.024,241.148,245.273,249.397,253.521,255.617,259.742,263.866,265.884,270.008,274.132" y="252.90700000000004" svg_rhmargin="278.256" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">pathologic N3 breast cancer. J Breast Cancer 2016;19:163</text>
  <text x="278.249" y="252.90700000000004" svg_rhmargin="281.985" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="281.991,286.116" y="252.90700000000004" svg_rhmargin="288.133" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text x="72.058,74.464,78.589,82.713,85.119,88.442,93.343,97.079,101.203,104.469,108.593,111.858,115.983,118.0,121.944,128.169,130.186,134.077,139.443,143.179,148.932,152.668,156.792,160.528,164.652,168.38799999999998,172.342,178.567,180.584,184.475,188.6,192.724,196.848,200.973,204.769,208.505,214.647,218.38299999999998,222.286,226.022,228.039,231.923,235.189,237.595,241.504,245.24,247.258,249.275,253.24,258.604,262.729,268.871,272.995,276.731,279.608,281.625,284.502,288.626,292.751,296.719,300.845,303.25100000000003,307.152,309.557,313.682" y="261.92100000000005" svg_rhmargin="316.947" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[35] Takeuchi H, Kawanaka H, Fukuyama S, et al. Comparison of the</text>
  <text x="88.442,92.567,95.443,99.568,103.304,107.428,111.553,114.429,116.835,118.853,122.118,126.084,129.82,133.556,135.573,139.697,143.034,145.911,149.837,153.961,156.36700000000002,160.324,164.449,167.325,170.59,174.78,178.904,182.169,185.046,188.782,191.188,193.205,196.941,200.206,204.202,206.219" y="270.879" svg_rhmargin="210.343" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">prognostic values of preoperative in</text>
  <text x="210.331" y="270.879" svg_rhmargin="214.455" style="fill:#171615;font-family:MMHCMO+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬂ</text>
  <text x="214.47,218.206,224.348,230.489,234.225,236.631,238.732,242.857,246.981,249.387,253.512,257.247,260.124,263.389,267.514,271.498,275.623,279.359,282.235,285.971,292.113,295.378,297.784,301.049,303.926,306.803,310.784,312.801" y="270.879" svg_rhmargin="316.925" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ammation-based parameters in</text>
  <text x="88.442,92.567,96.303,98.709,100.726,103.991,108.116,110.522,113.399,115.936,121.69,123.707,126.113,130.238,132.773,136.898,139.774,143.04,146.775,149.652,152.058,154.542,157.807,161.543,165.667,168.997,172.263,175.139,177.156,179.655,183.78,188.293,192.417,196.153,198.646,204.789,208.913,212.178,214.69,218.814,222.939,227.063,231.187,233.205,237.329,241.454,243.544,246.809,250.933,255.058,259.182,263.306,267.431,271.555,275.68" y="279.836" svg_rhmargin="277.697" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">patients with breast cancer. PLoS One 2017;12:e0177137.</text>
  <text x="72.058,74.464,78.589,82.713,85.119,88.442,94.666,97.931,100.807,104.932,108.668,112.792,116.917,120.182,123.447,128.124,133.488,140.96,142.977,147.625,155.097,158.833,162.957,165.834,169.958,174.083,177.819,182.432,187.796,191.921,193.938,198.588,203.953,207.689,210.954,215.078,219.203,222.468,225.73299999999998,230.39,234.515,237.392,243.145,245.162,249.835,253.101,255.507,260.097,263.832,265.85,267.867,272.512,277.876,280.753,284.018,286.424,290.549,292.566,296.774,300.039,302.916,305.793,310.436,314.561" y="288.793" svg_rhmargin="316.967" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[36] Hernández CM, Madrona AP, Vázquez PJG, et al. Usefulness of</text>
  <text x="88.442,90.46,94.196,100.337,104.462,108.586,112.711,115.976,119.712,122.118,125.383,127.789,130.195,134.416,136.822,142.964,147.089,151.213,155.337,158.603,162.338,164.744,168.01,170.027,174.835,178.96,182.225,186.349,188.755,191.632,195.756,199.881,204.086,206.104,208.121,210.527,212.933,217.057,219.463,225.605,229.73,233.854,237.978,241.244,244.98,247.385,250.64999999999998,255.503,259.239,263.363,267.488,272.34,276.464,279.729,283.854,286.26,289.136,293.261,297.385,301.51,303.527,305.544,307.95,310.356,314.481" y="297.75" svg_rhmargin="316.887" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-</text>
  <text x="88.442,90.46,94.196,100.337,104.462,108.586,112.711,115.976,119.712,122.118,125.383,126.99,129.867,133.603,136.009,138.026,142.15,145.02700000000002,146.604,150.34,153.217,154.768,158.893,161.77,165.894,169.63,173.816,177.94,180.817,183.223,185.24,188.505,190.086,196.228,199.963,202.84,206.965,210.23,213.106,215.983,217.58,219.597,223.722,225.29,229.414,232.291,235.556,239.292,242.169,244.57500000000002,246.151,249.416,253.152,257.277,260.542,263.807,266.684,268.259,272.384,276.12,278.526,280.543,283.808,287.933,290.339,293.216,294.846,297.252,300.129,303.394,307.13,309.536,312.801" y="306.707" svg_rhmargin="316.925" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lymphocyte ratios as prognostic markers in breast cancer patients treated</text>
  <text x="88.442,94.196,96.213,98.619,102.744,105.223,109.347,112.612,116.737,120.472,124.666,126.684,130.808,134.544,138.28,142.404,144.81,147.342,150.607,154.731,157.997,164.138,168.263,170.669,174.793,178.058,180.935,184.671,188.795,192.531,194.548,197.114,202.478,204.496,206.513,210.638,213.157,218.059,220.935,224.671,228.796,231.672,233.689,236.173,242.314,246.439,249.778,253.902,255.91899999999998,258.395,262.52,266.644,270.768,274.893,276.91,281.035,285.159,287.249,291.373,295.498" y="315.664" svg_rhmargin="299.622" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">with neoadjuvant chemotherapy. Clin Transl Oncol 2017;20:476</text>
  <text x="299.622" y="315.664" svg_rhmargin="303.358" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="303.364,307.489,311.615" y="315.664" svg_rhmargin="313.632" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">83.</text>
  <text x="72.058,74.464,78.589,82.713,85.119,88.442,94.583,96.601,100.726,104.258,110.012,112.029,115.54,119.276,123.401,127.525,131.261,134.758,140.123,142.14,145.643,151.007,155.132,157.149,160.722,166.087,168.10399999999998,171.606,174.872,177.27800000000002,180.79,184.526,186.543,188.56,192.072,194.478,198.602,201.867,204.744,208.009,211.745,214.622,217.887,222.012,225.575,229.699,232.964,237.089,239.495,242.371,246.496,250.62,254.744,256.762,258.779,261.185,263.203,266.938,273.192,277.317,281.441,285.566,288.831,292.567,294.973,298.238,301.764,304.64,308.376,310.782,312.8" y="324.678" svg_rhmargin="316.924" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[37] Qiu X, Song Y, Cui Y, et al. Increased neutrophil-lymphocyte ratio</text>
  <text x="88.442,90.46,94.584,98.709,101.974,106.098,109.363,113.488,117.612,120.877,125.002,127.408,129.425,133.161,136.457,140.581,143.458,146.723,150.848,152.865,156.13,158.622,161.49900000000002,164.745,168.87,172.994,177.118,179.995,183.226,186.103,190.227,193.104,196.84,198.929,202.665,206.4,208.417,211.684,213.701,217.826,221.094,225.219,229.343,233.468,235.874,242.016,245.281,247.687,251.423,254.299,256.705,260.441,262.847,264.864,268.12899999999996,271.433,273.839,276.716,278.733,282.858,284.875,288.14,290.546,294.671,297.936,301.672,305.503,307.909,309.926,313.662" y="333.636" svg_rhmargin="316.927" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">independently predicts poor survival in non-metastatic triple-negative</text>
  <text x="88.442,92.567,95.443,98.709,102.445,105.321,107.727,110.211,113.476,117.212,121.336,124.666,127.932,130.809,133.284,137.408,141.144,143.55,145.567,148.832,152.957,155.363,158.239,160.256,162.818,165.224,170.589,175.102,182.574,187.08700000000002,189.632,194.145,196.163,198.568,201.833,204.315,208.439,212.564,216.688,220.813,222.83,226.955,231.079,233.169,237.293,241.418" y="342.593" svg_rhmargin="245.542" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">breast cancer patients. IUBMB Life 2018;70:529</text>
  <text x="245.538" y="342.593" svg_rhmargin="249.274" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="259.547" x="249.28,253.405,257.53,259.54699999999997" y="37.75699999999995" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">35. </text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,354.187,357.453,361.577,365.313,368.105,371.841,377.206,380.01,384.134,387.87,389.887,392.708,396.833,400.958,403.706,409.071,413.196,415.213,418.049,423.413,427.538,431.274,435.398,439.134,441.914,448.138,455.61,457.627,460.395,466.537,469.802,474.0,476.406,479.283,483.407,487.532,491.656,493.674,495.691,498.49,500.896,505.021,507.787,509.805,513.54,519.682,523.807,527.931,532.056,535.394,539.13,541.536,544.8009999999999,547.582,550.459,554.195,556.601,558.618,562.743,565.553,567.57,570.447,573.263" y="37.75699999999995" svg_rhmargin="576.999" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[38] Geng SK FS, Fu YP, Zhang HW. Neutrophil to lymphocyte ratio is a</text>
  <text x="348.435,352.559,355.436,359.56,363.296,367.482,371.607,374.484,376.89,378.907,382.17199999999997,384.376,386.782,390.517,393.783,396.189,400.313,403.19,405.407,407.813,411.938,414.815,417.029,421.154,423.171,426.048,429.313,433.049,435.926,439.191,441.462,443.868,446.745,450.01,453.275,455.464,458.341,462.466,465.342,469.078,471.095,474.831,478.567,480.584,482.845,484.862,488.987,491.178,495.303,499.038,501.444,503.462,506.727,510.851,513.257,516.1339999999999,518.388,524.142,526.159,528.565,532.69,534.885,539.009,541.886,545.151,548.887,551.763,554.169,556.427,559.692,563.428,567.552,570.817,574.082" y="46.714000000000055" svg_rhmargin="576.959" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">prognostic factor for disease free survival in patients with breast cancer</text>
  <text x="348.435,352.559,356.684,360.808,364.073,366.95,372.703,376.042,380.167,382.573,385.056,388.321,392.446,395.322,399.058,401.464,403.482,407.218,410.483,413.004,415.88,419.146,422.022,425.362,428.627,431.033,433.051,437.175,441.299,443.316,445.827,453.299,456.564,460.689,462.706,465.971,467.989,472.113,475.378,477.913,482.038,486.162,490.287,494.411,496.428,500.553,504.677,506.767,510.032,514.157,518.281,522.406,526.53,530.655" y="55.67100000000005" svg_rhmargin="532.672" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">underwent curative resection. Medicine 2018;97:e11898.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,352.947,356.212,359.477,361.246,364.123,366.14,367.879,373.244,375.262,381.404,383.129,388.883,396.354,398.371,400.136,404.649,407.914,411.179,412.948,418.313,420.33,422.075,426.2,429.076,433.201,436.937,441.061,445.186,448.062,450.468,452.486,455.751,457.505,460.382,464.506,466.524,469.789,471.564,475.3,479.424,483.549,485.283,488.548,490.565,492.583,496.707,498.725,501.99,505.726,507.743,509.489,513.224,516.101,518.978,523.102,526.367,528.385,532.121,534.527,536.544,540.669,544.794,546.563,550.688,553.0939999999999,554.84,557.246,561.37,567.512,571.636,574.513" y="64.62800000000004" svg_rhmargin="576.919" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[39] Lee J, Kim DM, Lee A. Prognostic role and clinical association of tumor-</text>
  <text x="348.435,350.452" y="73.58600000000001" svg_rhmargin="354.576" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">in</text>
  <text x="354.614" y="73.58600000000001" svg_rhmargin="358.738" style="fill:#171615;font-family:MMHCMO+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="358.753,360.77,363.176,366.053,369.788,372.194,374.212,378.336,382.072,385.85,387.867,391.603,397.745,401.869,405.994,410.118,413.457,417.193,419.598,422.864,424.881,428.649,432.773,435.65,439.775,443.51,446.387,450.123,456.265,462.407,465.672,469.797,473.603,477.727,480.993,484.729,487.134,491.259,495.088,497.106,499.123,502.859,506.595,510.719,514.844,517.25,521.375,525.133,528.398,532.523,536.647,539.589,542.854,545.731,548.607,550.625,554.749,558.874,562.662,568.415,570.432,572.838" y="73.58600000000001" svg_rhmargin="576.962" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ltrating lymphocyte, programmed death ligand-1 expression with</text>
  <text x="348.435,352.559,355.824,359.949,362.355,365.231,369.356,373.48,377.686,379.703,381.721,384.127,386.144,389.88,396.022,400.146,404.271,408.395,411.66,415.396,417.802,421.067,424.227,427.104,430.84,433.246,435.263,439.388,442.538,444.555,448.68,451.778,453.795,457.92,461.185,464.921,466.938,468.956,472.692,475.814,479.55,483.674,487.41,491.146,495.27,498.536,501.801,505.926,509.034,511.439,514.316,516.333,520.542,522.559,525.824,528.23,532.355,535.62,539.356,543.092,545.497,547.515,551.251,554.516,557.673,561.797,564.674,567.939,571.675,574.552" y="82.543" svg_rhmargin="576.958" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">neutrophil-lymphocyte ratio in locally advanced triple-negative breast</text>
  <text x="348.435,351.7,355.436,359.56,362.825,366.091,368.967,370.984,373.548,378.912,382.648,386.773,390.038,393.303,396.18,398.717,404.082,407.347,410.224,412.719,417.621,420.498,423.763,427.499,429.90500000000003,432.448,436.572,440.696,444.821,448.945,450.963,455.087,459.212,461.229,463.246,465.78,469.904,474.029,476.046,480.171,484.295,488.42,492.544,494.561,497.827,500.703,503.109,505.126,509.251,513.375,517.592,521.717,523.734,527.859,531.983,536.108" y="91.55700000000002" svg_rhmargin="538.125" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cancer. Cancer Res Treat 2018;doi: 10.4143/crt.2018.270.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,352.947,354.964,359.089,361.076,366.83,368.847,370.77,376.913,381.038,383.016,385.892,391.257,393.274,395.204,400.569,404.693,408.429,412.553,416.289,418.219,421.096,423.113,425.079,428.344,430.75,432.732,436.468,438.486,440.503,442.426,446.551,449.427,453.552,457.288,461.412,465.537,468.413,470.819,472.836,476.101,478.083,480.96,485.084,487.102,490.36699999999996,492.312,496.437,498.843,500.816,504.94,507.817,511.082,513.488,516.365,519.63,523.366,525.772,531.914,535.179,539.303,541.709,543.729,547.853,551.119,555.243,557.649,560.526,564.65,568.775,572.899,574.916" y="100.51400000000001" svg_rhmargin="576.933" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[40] Liu X, Qu JK, Zhang J, et al. Prognostic role of pretreatment neutrophil</text>
  <text x="348.435,350.841,354.966,356.995,359.013,362.749,368.89,373.015,377.139,381.264,384.602,388.338,390.744,394.009,396.053,398.93,402.666,405.072,407.089,411.214,413.23,415.248,419.373,421.451,425.575,428.452,431.717,435.453,438.329,440.735,442.765,446.031,449.766,453.891,457.156,460.421,463.298,465.327,469.452,473.188,475.593,477.686,480.951,485.075,487.481,490.358,492.375,494.409,498.145,500.191,506.334,509.599,512.005,515.741,518.147,521.883,526.007,529.743,531.76,535.496,538.373,540.39,543.267,545.2840000000001,547.356,554.828,558.093,562.218,564.306,567.571,569.589,573.713" y="109.471" svg_rhmargin="576.978" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine</text>
  <text x="348.435,352.559,356.684,360.808,364.932,366.95,371.074,375.199,377.289,380.554,384.678,388.803,392.927,397.051" y="118.42899999999997" svg_rhmargin="399.068" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2017;96:e8101.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,352.947,355.353,359.477,361.495,364.76,367.637,369.579,372.456,376.969,378.876,384.63,390.383,392.4,394.353,399.254,402.519,408.661,412.786,414.803,418.068,420.474,424.599,428.724,430.69,436.055,438.072,439.987,443.723,447.848,451.584,455.709,457.675,461.799,463.816,465.725,468.99,471.396,473.321,477.057,479.075,481.092,483.015,487.14,490.016,494.141,497.877,502.001,506.126,509.002,511.408,513.425,516.6899999999999,518.615,521.492,525.617,527.634,530.899,532.845,536.969,539.375,541.292,545.416,548.681,552.806,555.212,558.088,562.213,566.337,570.462,572.479,574.497" y="127.38599999999997" svg_rhmargin="576.903" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[41] Ethier JL DD, Templeton A, Shah P, et al. Prognostic role of neutrophil-</text>
  <text x="348.435,350.841,354.965,357.371,359.388,363.124,369.353,373.477,377.602,381.726,384.991,388.727,391.133,394.39799999999997,397.923,400.8,404.536,406.942,409.034,413.159,416.687,418.705,422.83,426.381,430.506,433.382,436.648,440.383,443.26,445.666,449.227,452.492,456.228,460.353,463.618,466.883,469.76,471.777,475.36,479.096,482.617,485.494,489.23,492.106,494.512,497.777,503.919,507.655,510.061,512.078,515.343,518.954,521.831,525.096,528.832,530.849,534.114,539.8670000000001,543.443,547.179,551.304,555.429,558.977,565.119,568.384,570.79,574.526" y="136.34299999999996" svg_rhmargin="576.932" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">to-lymphocyte ratio in breast cancer: a systematic review and meta-</text>
  <text x="348.435,352.171,356.295,360.031,362.048,365.784,368.729,370.746,373.623,375.64,378.14,382.653,385.529,388.795,392.53,395.407,397.813,400.305,405.67,409.405,413.53,416.795,420.06,422.937,425.474,430.839,434.104,436.981,439.533,443.658,447.782,451.906,456.031,458.048,462.173,466.297,468.315,472.439" y="145.35699999999997" svg_rhmargin="474.456" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">analysis. Breast Cancer Res 2017;19:2.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,352.17,356.294,360.419,364.155,367.141,370.877,372.894,375.814,380.327,382.344,385.339,390.704,392.721,395.657,400.17,402.187,405.124,408.86,410.877,413.854,417.119,419.52500000000003,422.471,426.207,428.225,430.242,433.186,438.939,442.204,445.081,447.098,450.834,454.1,458.225,461.247,465.371,468.637,472.761,475.167,478.044,482.168,486.292,490.417,492.434,494.451,497.414,499.82,503.945,506.882,508.899,512.635,518.777,522.981,527.106,531.23,534.495,538.231,540.637,543.9019999999999,546.847,549.724,553.46,555.866,557.883,562.008,564.988,568.724,572.848" y="154.31399999999996" svg_rhmargin="576.972" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[42] Song S, Li C, Li S, et al. Derived neutrophil to lymphocyte ratio and</text>
  <text x="348.435,354.577,358.701,362.825,366.95,370.215,373.951,376.438,379.703,382.051,384.457,388.582,391.008,393.026,396.762,402.903,407.028,411.152,415.277,418.542,422.278,424.684,427.949,430.406,433.283,437.019,439.425,441.442,445.567,447.98,454.122,457.858,461.594,463.967,468.092,471.35699999999997,473.775,477.9,481.165,483.571,485.977,489.242,492.119,494.523,498.648,500.665,504.789,510.931,514.667,517.544,521.668,525.022,527.898,530.775,533.129,535.535,539.659,542.536,544.977,549.101,551.978,555.243,559.367,561.385,564.65,567.056,569.073,573.198" y="163.27099999999996" svg_rhmargin="576.934" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">monocyte to lymphocyte ratio may be better biomarkers for predicting</text>
  <text x="348.435,352.559,356.295,359.56,362.437,366.173,368.19,370.207,372.528,375.404,379.529,382.405,386.141,388.159,391.895,395.63,397.647,399.965,404.089,406.495,408.808,412.933,416.669,419.075,421.092,424.357,428.482,430.888,433.765,436.075,441.829,443.846,446.252,450.377,452.685,456.421,460.545,464.281,468.017,472.142,475.407,478.672,482.797,485.11,488.846,492.582,495.459,497.865,500.741,502.759,506.024,508.296,511.561,515.297,519.422,522.752,526.017,528.894,530.9110000000001,533.183,539.324,543.449,546.714,550.839,553.137,558.039,561.775,564.652,568.388,571.653,574.059" y="172.22900000000004" svg_rhmargin="576.936" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">overall survival of patients with advanced gastric cancer. Onco Targets</text>
  <text x="348.435,353.336,357.461,360.726,363.603,366.122,370.246,374.371,378.495,382.62,384.637,388.762,392.886,394.976,399.1,403.225,407.349" y="181.18600000000004" svg_rhmargin="411.473" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Ther 2017;10:3145</text>
  <text x="411.477" y="181.18600000000004" svg_rhmargin="415.213" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="415.219,419.344,423.469" y="181.18600000000004" svg_rhmargin="425.486" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">54.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,353.799,357.535,361.659,365.784,369.976,373.241,376.439,383.911,385.928,389.137,394.891,396.908,400.644,404.768,408.893,412.629,415.505,418.771,420.788,422.805,424.822,428.082,433.835,435.852,439.08,446.551,450.287,452.305,454.322,458.058,460.935,465.059,469.184,472.413,478.166,480.183,483.411,486.676,489.082,492.311,496.047,498.064,500.081,503.252,507.765,511.501,514.378,517.708,519.725,521.742,525.867,529.132,532.334,536.458,539.723,543.848,546.254,549.13,553.255,557.379,561.504,563.521,565.539,567.945,570.351,574.475" y="190.14300000000003" svg_rhmargin="576.881" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[43] Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-</text>
  <text x="348.435,350.452,354.188,360.33,364.454,368.579,372.703,376.042,379.777,382.183,385.448,387.379,390.256,393.992,396.398,398.415,402.54,404.443,406.849,412.99,417.503,422.868,425.274,427.232,430.967,435.092,439.217,441.177,445.301,448.567,451.443,453.461,457.196,460.462,464.587,466.517,472.659,477.172,482.53700000000003,484.487,487.752,491.877,496.001,498.019,502.144,504.045,508.169,511.046,514.311,518.435,520.453,523.718,526.1239999999999,528.081,532.205,535.941,539.206,542.083,545.819,547.836,549.8530000000001,551.833,554.71,558.834,561.711,565.447,567.464,571.2,574.936" y="199.10000000000002" svg_rhmargin="576.953" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lymphocyte ratio (NLR) and derived NLR could predict overall survival</text>
  <text x="348.435,350.452,354.577,361.303,365.428,369.164,371.57,373.587,376.852,380.977,383.383,386.26,392.993,398.746,400.764,403.169,407.294,414.024,417.76,421.885,425.621,429.357,433.481,436.746,440.011,444.136,450.872,457.014,460.279,462.297,466.033,470.157,474.281,480.423,484.159,490.894,493.3,496.177,499.442,503.178,505.584,508.849,512.9739999999999,519.692,525.445,527.463,529.953,534.078,540.724,544.849,546.866,550.602,554.727,556.824,560.948,567.09,570.826,574.951" y="208.11400000000003" svg_rhmargin="576.968" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">in patients with advanced melanoma treated with nivolumab.</text>
  <text x="348.435,351.312,353.82,356.226,362.368,368.51,372.634,376.759,380.883,383.289,387.414,390.679,393.556,396.109,401.474,405.21,409.334,412.6,415.865,418.742,421.279,425.403,429.528,433.652,437.776,439.794,443.918,445.936,450.133,454.257" y="217.07100000000003" svg_rhmargin="456.274" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">J Immunother Cancer 2018;6:74.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,350.84,354.964,357.841,361.577,365.701,367.719,373.861,377.062,380.798,386.163,388.18,391.404,396.77,400.506,402.912,406.648,409.524,413.26,416.462,422.215,427.58,429.597,432.788,438.153,441.03,445.154,447.172,449.578,453.31399999999996,456.484,461.849,463.866,467.085,470.351,472.757,475.929,479.665,481.682,483.699,486.87,491.383,494.26,497.525,501.261,504.137,506.543,509.716,512.981,516.717,520.841,524.172,527.437,530.314,533.469,537.205,540.081,542.958,547.082,550.348,552.365,556.101,558.507,561.772,565.897,569.126,572.862" y="226.029" svg_rhmargin="576.986" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[44] Ibrahim SA, Katara GK, Arpita K, et al. Breast cancer associated a2</text>
  <text x="348.435,350.452,353.329,357.453,359.859,363.984,366.86,373.002,375.306,379.042,382.777,386.043,390.167,394.353,396.37,400.106,402.983,405.237,410.602,415.503,419.693,423.428,426.305,429.57,431.825,433.842,439.984,446.126,450.25,454.374,458.499,464.641,468.765,472.98,477.104,479.122,482.858,485.264,488.529,491.406,493.672,497.796,501.061,505.186,507.591,510.468,514.593,518.717,522.923,524.94,526.958,529.834,531.851,534.148,538.272,542.397,544.803,548.068,552.192,554.598,556.616,560.352,562.369,564.646,567.523,571.647,573.665" y="234.986" svg_rhmargin="576.93" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">isoform vacuolar ATPase immunomodulates neutrophils: potential role</text>
  <text x="348.435,350.452,354.577,357.109,359.515,363.639,369.781,373.905,376.782,379.274,383.398,386.275,390.399,394.135,397.012,400.277,403.154,406.03,408.128,412.252,416.377,418.394,420.883,427.025,431.149,434.414,438.539,440.945,444.68,447.639,451.375,454.64,457.046,459.544,463.669,467.793,471.917,476.042,478.059,482.184,484.201,488.325,492.45,496.574,500.699" y="243.94299999999998" svg_rhmargin="504.823" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">in tumor progression. Oncotarget 2015;6:33033</text>
  <text x="504.906" y="243.94299999999998" svg_rhmargin="508.642" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="508.648,512.773,516.898" y="243.94299999999998" svg_rhmargin="518.915" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">45.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,355.906,359.171,363.295,365.313,368.578,372.703,377.175,380.911,386.276,388.293,392.708,400.181,403.917,405.934,409.67,413.794,417.06,421.184,423.201,427.629,430.035,432.052,436.473,442.615,445.88,450.079,452.485,455.361,459.486,463.61,467.735,469.752,471.769,474.646,479.104,481.98,486.105,490.229,494.354,498.478,501.355,503.761,508.185,510.202,514.327,518.451,522.187,526.609,529.874,533.998,536.016,540.14,544.265,546.282,549.547,553.283,555.689,557.706,561.831,565.956,570.429,574.553" y="252.89999999999998" svg_rhmargin="576.959" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[45] Wculek SK, Malanchi I. Neutrophils support lung colonization of</text>
  <text x="348.435,354.577,357.842,360.248,363.984,366.86,369.353,373.089,375.965,377.983,380.859,383.265,385.283,389.407,391.425,393.83,395.848,399.584,401.99,404.007,408.132,411.868,414.42,418.544,421.421,424.686,428.422,431.299,433.705,436.245,439.51,443.246,447.37,450.636,453.901,456.778,459.317,462.582,465.847,467.865,469.882,472.759,474.776,477.287,483.429,487.165,489.571,493.695,496.572,499.837,502.4,506.525,510.649,514.773,518.898,520.915,525.04,529.164,533.289,535.306,539.43,543.555" y="261.914" svg_rhmargin="547.679" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">metastasis-initiating breast cancer cells. Nature 2015;528:413</text>
  <text x="547.709" y="261.914" svg_rhmargin="551.445" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="551.451,555.576" y="261.914" svg_rhmargin="557.593" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">7.</text>
  <text x="332.051,334.457,338.581,342.705,345.111,348.434,352.17,355.906,358.783,362.518,366.643,368.65999999999997,371.677,375.412,377.429,380.407,384.92,388.656,392.78,396.51599999999996,399.511,404.412,406.429,409.432,416.903,421.028,423.904,427.64,431.765,435.501,439.625,443.361,446.336,452.56,454.577,457.56,460.826,463.232,466.234,469.97,471.988,474.005,477.006,479.412,483.536,487.272,491.396,493.414,497.15,500.415,506.557,509.822,513.946,516.352,519.408,523.533,525.939,528.876,533.0,535.877,540.001,544.126,546.143,550.268,553.533,556.029,558.047,561.312,563.329,567.454,570.428,574.553" y="270.871" svg_rhmargin="576.959" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[46] Sasaki S, Baba T, Muranaka H, et al. Involvement of prokineticin 2-</text>
  <text x="348.435,351.7,355.824,359.949,362.825,366.091,368.967,371.844,373.944,378.069,381.805,384.205,388.33,391.595,395.719,398.125,401.002,405.126,409.251,413.457,415.474,417.491,419.92,421.937" y="279.82899999999995" svg_rhmargin="426.061" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">expressing neutrophil in</text>
  <text x="426.103" y="279.82899999999995" svg_rhmargin="430.227" style="fill:#171615;font-family:MMHCMO+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="430.242,432.259,434.665,437.542,441.278,443.684,445.701,449.826,453.951,456.432,458.45,462.575,464.993,469.117" y="279.82899999999995" svg_rhmargin="471.523" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ltration in 5-</text>
  <text x="471.571" y="279.82899999999995" svg_rhmargin="475.695" style="fill:#171615;font-family:MMHCMO+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬂ</text>
  <text x="475.709,479.834,483.958,486.835,490.959,495.084,497.96,501.696,504.962,506.979,508.996,511.402,513.42,517.544,521.669,525.793,529.058,532.323,536.448,538.973,542.709,546.445,550.181,553.058,556.794,560.529,564.265,566.671,568.689,572.813" y="279.82899999999995" svg_rhmargin="576.937" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">uorouracil-induced aggravation</text>
  <text x="348.435,352.559,354.96500000000003,356.825,360.949,363.826,367.091,370.827,373.704,376.11,377.913,381.178,384.914,389.039,392.304,395.569,398.446,400.305,406.447,409.712,412.118,415.854,418.731,421.137,424.873,427.749,429.767,432.644,434.488,436.894,441.019,442.878,444.896,449.02,453.145,456.88,458.897,460.678,468.15,472.275,474.292,476.155,481.52,485.256,489.38,492.646,495.911,498.788,500.645,505.546,509.671,512.936,515.813,517.595,521.719,525.844,529.968,534.093,536.11,540.234,544.359,546.449,550.573,554.698,558.822" y="288.786" svg_rhmargin="562.946" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">of breast cancer metastasis to lung. Mol Cancer Ther 2018;17:1515</text>
  <text x="562.96" y="288.786" svg_rhmargin="566.696" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="566.702,570.827,574.952" y="288.786" svg_rhmargin="576.969" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">25.</text>
  <text x="332.051,334.457,338.582,342.706,345.112,348.435,354.188,358.313,362.437,366.173,368.579,370.596,372.528,377.892,379.909,381.768,385.504,388.769,392.893,397.018,399.035,401.44100000000003,403.309,408.674,410.691,412.55,417.914,422.039,425.304,429.499,432.37600000000003,434.205,440.347,442.364,444.239,447.504,449.91,451.779,455.515,457.532,459.549,461.416,467.558,470.823,474.947,477.353,480.23,484.431,488.556,492.68,494.697,496.715,499.121,503.245,506.51,509.387,511.404,515.14,518.405,522.53,524.453,526.47,530.595,533.001,536.266,539.143,541.16,544.425,548.55,552.674,554.692,558.817,560.734,564.859,568.984,570.825,572.842" y="297.743" svg_rhmargin="576.966" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[47] Donati K, Sépult C, Rocks N, et al. Neutrophil-derived interleukin 16 in</text>
  <text x="348.436,352.56,355.437,358.702,364.844,368.109,370.601,374.337,377.213,379.619,383.355,385.761,387.778,391.043,393.106,395.123,399.247,403.372,407.108,409.985,411.983,416.108,418.984,423.109,429.33,433.455,435.861,439.126,442.003,444.013,448.138,451.014,454.279,458.015,460.892,463.298,465.385,467.791,471.915,478.057,482.181,485.058,487.096,490.362,493.627,495.644,497.661,499.681,502.558,505.823,509.088,513.286,515.304,519.428,523.164,525.181,527.175,532.54,536.276,540.4,543.665,547.016,549.8929999999999,551.891,557.645,560.522,564.646,570.4,572.806" y="306.7" svg_rhmargin="576.93" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">premetastatic lungs promotes breast tumor cell seeding. Cancer Growth</text>
  <text x="348.436,355.907,359.173,361.578,365.314,368.191,370.597,374.333,377.289,379.307,382.184,384.66,388.784,392.908,397.033,401.157,403.175,407.299,411.424,413.513,417.638,421.762,425.887,430.011,434.135,438.26,442.384,446.509,450.633,454.758,458.882,463.006,467.197,471.321,475.445" y="315.657" svg_rhmargin="477.462" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Metastasis 2017;10:179064417738513.</text>
  <text svg_rhmargin="543.734" x="332.051,334.457,338.582,342.706,345.112,348.435,353.8,357.924,360.33,362.736,366.001,368.106,370.512,372.812,376.547,381.06,383.077,385.453,390.818,394.083,396.96,399.836,402.242,405.507,409.632,411.983,417.348,419.365,421.734,427.487,431.612,435.736,438.613,442.737,446.002,450.127,453.863,455.88,458.241,463.606,471.078,473.09499999999997,475.418,478.683,481.089,483.468,487.204,489.221,491.238,493.559,495.965,500.478,504.602,508.726,511.132,515.257,518.218,522.342,526.467,530.591,533.856,535.874,539.998,543.734" y="324.671" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[48] Coffelt SB, Kersten K, Doornebal CW, et al. IL17-producing </text>
  <text svg_rhmargin="553.927" x="546.066,550.191,553.927" y="324.671" style="fill:#171615;font-family:MMNFHG+AdvP7DA6;font-size:7.47px;font-style:NORMAL;font-weight:normal;">gd </text>
  <text x="556.271,561.173,563.528,566.793,570.058,572.076,574.093" y="324.671" svg_rhmargin="576.97" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">T cells</text>
  <text x="348.436,352.172,356.297,360.422,363.345,367.47,370.735,374.859,377.265,380.142,384.266,388.391,392.515,394.533,396.55,399.427,402.347,405.612,409.736,413.861,416.802,420.927,422.944,425.821,429.086,431.996,434.401,438.526,441.406,445.531,448.407,452.532,458.674,462.798,465.204,468.469,471.394,475.519,478.396,481.661,485.397,488.274,490.68,493.617,496.882,500.618,504.742,508.008,511.273,514.15,517.086,523.228,526.493,528.899,532.635,535.511,537.917,541.653,544.53,546.547,549.424,551.441,554.387,560.528,564.264,566.67,570.795,573.671" y="333.629" svg_rhmargin="576.936" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">and neutrophils conspire to promote breast cancer metastasis. Nature</text>
  <text x="348.436,352.561,356.685,360.81,364.934,366.951,371.076,375.2,379.325,381.429,385.553,389.678" y="342.586" svg_rhmargin="393.802" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2015;522:345</text>
  <text x="393.79" y="342.586" svg_rhmargin="397.526" style="fill:#171615;font-family:MMHCMP+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="397.532,401.656" y="342.586" svg_rhmargin="403.673" style="fill:#171615;font-family:MMHCMN+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text svg_rhmargin="188.466" x="71.887,77.282,81.515,85.579,89.81099999999999,92.409,96.474,98.793,101.48,105.545,106.955,109.107,111.741,118.292,122.357,126.916,128.327,132.392,133.802,138.034,142.099,144.678,146.583,150.983,155.382,159.782,164.182,166.087,168.715,173.115,177.514,179.666,184.066,188.465" y="9.870999999999981" style="fill:#171615;font-family:MMHCLI+AdvOT6e5d2ec0;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Duan et al. Medicine (2018) 97:49 </text>
  <text x="542.723,549.944,554.503,559.317,561.31,565.869,567.861,572.508" y="9.870999999999981" svg_rhmargin="577.067" style="fill:#171615;font-family:MMHCLH+AdvOT34fe1490.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Medicine</text>
  <text x="320.032,324.432" y="739.625" svg_rhmargin="328.832" style="fill:#171615;font-family:MMHDEE+AdvOTf94803d4;font-size:7.97px;font-style:NORMAL;font-weight:normal;">10</text>
 </g>
</svg>
